Lantheus Holdings, Inc. LNTH

Company Overview

Lantheus Holdings, Inc. is a U.S.-based radiopharmaceutical company focused on diagnostic imaging and targeted therapeutics for oncology, cardiology, and neurology applications. The company develops, manufactures, and commercializes radiopharmaceuticals and artificial intelligence-enabled imaging solutions used primarily in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) procedures. Lantheus operates within the broader healthcare, medical imaging, and nuclear medicine industries, with a strategic emphasis on precision diagnostics and theranostics. Its principal revenue drivers include prostate cancer imaging agent PYLARIFY, contrast agents, ultrasound enhancing agents, and nuclear imaging products used in hospitals, imaging centers, and physician practices.

Lantheus traces its origins to the medical imaging business historically associated with Bristol-Myers Squibb and later acquired by Avista Capital Partners before becoming publicly traded in 2015. The company has evolved from a traditional diagnostic imaging supplier into a radiopharmaceutical-focused enterprise centered on oncology imaging and targeted therapy development. Its strategic positioning has been strengthened through proprietary isotope supply arrangements, manufacturing capabilities, and commercialization infrastructure in nuclear medicine, particularly in prostate-specific membrane antigen (PSMA)-targeted imaging.